About
Titles
Assistant Professor
Appointments
Education & Training
- MD
- Vanderbilt University School of Medicine (2019)
- BA
- University of Virginia
Research
Research at a Glance
Publications Timeline
A big-picture view of Jessica Burris's research output by year.
7Publications
68Citations
Publications
2023
Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab. Digestive Diseases And Sciences 2023, 68: 3413-3420. PMID: 37115362, DOI: 10.1007/s10620-023-07942-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsShort Crohn's Disease Activity IndexDisease activity indexCrohn's diseasePain interferenceCorticosteroid useTreatment persistenceSecondary outcomesAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsCrohn's Disease Activity IndexEffectiveness of vedolizumabHigher corticosteroid useLower treatment persistenceNecrosis factor therapyCo-primary outcomesPatient-reported outcomesInternet-based cohort studyLogistic regression modelsIBD PartnersCohort studyExperienced patientsFactor therapyPrimary outcomeBiological therapySteroid use
2022
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease
Kappelman M, Adimadhyam S, Hou L, Wolfe A, Smith S, Simon A, Moyneur É, Reynolds J, Toh S, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Dawwas G, Lewis J, Long M. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease. The American Journal Of Gastroenterology 2022, 118: 674-684. PMID: 36508681, DOI: 10.14309/ajg.0000000000002068.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCrohn's diseaseCause hospitalizationCD hospitalizationsTreatment persistenceSecondary outcomesAntitumor necrosis factor therapyReal-world comparative effectiveness studiesAntitumor necrosis factorLarge US insurerNecrosis factor therapyTreatment persistence ratesAnti-TNF treatmentBaseline clinical characteristicsRetrospective cohort studyComparative effectiveness studiesRoute of administrationDiverse US populationLongitudinal claims dataRefractory populationClinical characteristicsCohort studyFactor therapyPrimary outcomePatient preferencesNecrosis factorS934 Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. S934 Comparative Effectiveness of Vedolizumab Versus Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease. The American Journal Of Gastroenterology 2022, 117: e676-e676. DOI: 10.14309/01.ajg.0000860376.18652.65.Peer-Reviewed Original ResearchS738 Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease
Kappelman M, Adimadhyam S, Hou L, Simon A, Dobes A, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand J, Long M. S738 Real World Evidence Comparing Vedolizumab and Ustekinumab in Anti-TNF Experienced Patients With Crohn’s Disease. The American Journal Of Gastroenterology 2022, 117: e519-e520. DOI: 10.14309/01.ajg.0000859592.38187.d3.Peer-Reviewed Original ResearchTu1436: SYSTEMIC CORTICOSTEROIDS BUT NOT ANTI-TNF ARE ASSOCIATED WITH INCREASED RISK OF HOSPITALIZATION, INTENSIVE CARE, AND DEATH AMONG PATIENTS WITH IBD: RESULTS FROM A LARGE, POPULATION-BASED COHORT
Kappelman M, Parlett L, Haynes K, Selvan M, Ma Q, Nair V, Adimadhyam S, Hou L, Wolfe A, Toh D, Burris J, Dorand J, Lewis J, Long M. Tu1436: SYSTEMIC CORTICOSTEROIDS BUT NOT ANTI-TNF ARE ASSOCIATED WITH INCREASED RISK OF HOSPITALIZATION, INTENSIVE CARE, AND DEATH AMONG PATIENTS WITH IBD: RESULTS FROM A LARGE, POPULATION-BASED COHORT. Gastroenterology 2022, 162: s-959. DOI: 10.1016/s0016-5085(22)62274-1.Peer-Reviewed Original Research
2018
Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network
Chung AE, Vu MB, Myers K, Burris J, Kappelman MD. Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network. Medical Care 2018, 56: s33-s40. PMID: 30074949, PMCID: PMC6143211, DOI: 10.1097/mlr.0000000000000771.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2016
Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn’s and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners)
Chung AE, Sandler RS, Long MD, Ahrens S, Burris JL, Martin CF, Anton K, Robb A, Caruso TP, Jaeger EL, Chen W, Clark M, Myers K, Dobes A, Kappelman MD. Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn’s and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners). Journal Of The American Medical Informatics Association 2016, 23: 485-490. PMID: 26911821, PMCID: PMC4901381, DOI: 10.1093/jamia/ocv191.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsInflammatory bowel diseasePatient-powered research networksPatient-centered outcomes researchPerson-generated health dataColitis FoundationPatient-centered research agendaIndividual patient dataOutcomes researchHealth dataHealth care decisionsResearch NetworkBowel diseaseHealth behaviorsComparative effectivenessCrohn'sCare decisionsPatient dataTranslational researchPatientsDisease
Academic Achievements and Community Involvement
honor Founder's Medal
Other AwardVanderbilt UniversityDetails05/10/2019United Stateshonor Beauchamp Prize in Psychiatry
Other AwardVanderbilt University Medical CenterDetails05/09/2019United States